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ABSTRACT
The majority of patients with advanced epithelial 
ovarian cancer respond to primary platinum/
taxane-based combination chemotherapy. 
Unfortunately, recurrence is the rule rather 
than the exception in this clinical setting. In 
addition, multiple trials focused on the addition 
of a “third” cytotoxic drug to a platinum/taxane 
combination have failed to demonstrate any 
improvement in outcome. However, recent data 
reveal that addition of the antiangiogenic agent, 
bevacizumab, to either a primary platinum-
based chemotherapy program or platinum-
based therapy to manage recurrent disease 
can substantially improve time to subsequent 
disease progression and potentially favorably 
affect overall survival. This review discusses 
the rationale supporting the combination 
of cytotoxic and antiangiogenic therapy in 
advanced epithelial ovarian cancer, the existing 
evidence-based data supporting this strategy, 
and possible future research directions in this 
difficult malignancy.
Keywords: antiangiogenic therapy; combination 
chemotherapy; epithelial ovarian cancer
INTRODUCTION
Epithelial ovarian cancer is one of the most 
chemosensitive of all solid (nonhematologic) 
malignancies. Following primary platinum-
based (most frequently, carboplatin) therapy, 
60%-80% of patients will be anticipated to 
achieve both a major objective (eg, substantial 
shrinkage of measurable tumor masses, decline 
in serum cancer antigen 125 antigen levels) 
and subjective (eg, decrease in pain, reduction 
in malignant ascites formation) improvement 
in their disease (Table 1) [1]. Furthermore, a 
relatively large number of cytotoxic drugs have 
been shown to be biologically active when 
administered to patients whose cancers have 
either failed to respond to, or have progressed 
M. Markman ()
Cancer Treatment Centers of America,  
Eastern Regional Medical Center, 1331 East Wyoming 
Avenue, Philadelphia, PA 19124, USA.
Email: maurie.markman@ctca-hope.com
2 Comb Prod Ther (2011)  1(1):004
relatively quickly following the completion of 
platinum-based treatment [1].
Both currently employed primary and 
second-line chemotherapy approaches 
have clearly been documented to improve 
survival (both overall and the time to disease 
progression) and to have a favorable affect on 
cancer-associated symptoms. However, it has 
been recognized by the ovarian cancer research 
community and physicians who regularly 
or infrequently manage this disease that a 
“plateau” appears to have been reached in 
improving clinical outcomes by simply finding 
new cytotoxic drugs or by combining existing 
agents in novel programs [1].
For example, in an important study involving 
major international collaborations, 2000 
patients with advanced ovarian cancer were 
randomized to one of four unique three-drug 
combination cytotoxic chemotherapy regimens 
or to the “gold standard” of carboplatin 
plus paclitaxel [2]. Unfortunately, this study 
revealed no difference in either progression-
free survival (PFS) or overall survival between 
any of the treatment regimens. As a result 
of this and similar efforts that have failed to 
demonstrate improved survival outcomes 
associated with combining cytotoxics in this 
clinical setting, there has been considerable 
interest in discovering and subsequently testing 
alternative systemic treatment approaches in the 
management of ovarian cancer.
ANGIOGENESIS AND THE USE OF 
ANTIANGIOGENIC AGENTS IN 
OVARIAN CANCER
The process of angiogenesis has been well 
recognized to play a central role in normal 
ovarian function and reproductive physiology 
[3]. In addition, solid preclinical and clinical 
data have demonstrated the substantial negative 
association between evidence of a potent 
angiogenic effect in individual tumors (eg, 
high tissue expression, elevated serum levels 
of angiogenic factors) and overall survival in 
patients with ovarian cancer [4,5].
These provocative observations led 
investigators to explore the potential clinical 
utility of a number of pharmaceutical agents 
whose biological activity has been hypothesized 
to be due (at least in part) to their ability to 
strongly inhibit angiogenesis (antiangiogenic 
effect).
Bevacizumab, an inhibitor of vascular 
endothelial growth factor is the drug in this 
category that has been most extensively 
evaluated in the management of epithelial 
ovarian cancer.
Severa l  s ingle  agent  bevac izumab 
trials conducted in patients with ovarian 
cancer whose malignancy had progressed 
after one or more previous cytotoxic 
antineoplastic regimens have confirmed 
impressive biological activity for the 
drug ,  wi th  approximate ly  15%-20%
of individuals observed to have achieved a 
measurable effect (confirmed by response 
evaluation criteria in solid tumors [RECIST] 
criteria) [6,7]. In addition, in one cooperative 
group study a number of patients treated 
with single agent bevacizumab appeared to 
experience a rather unexpected extension of 
the time to subsequent disease progression 
when compared with a “historical control” 
Carboplatin (AUC 5-7.5) plus paclitaxel (175 mg/m2 
over 3 hours)
Carboplatin (AUC 6) plus paclitaxel  (80 mg/m2/week)
Carboplatin (AUC 5-6) plus docetaxel (60-75 mg/m2)
Cisplatin (75 mg/m2) plus paclitaxel (135 mg/m2 over 
24 hours)
Table 1. Standard primary cytotoxic chemotherapy 
regimens in the management of epithelial ovarian cancer.
AUC=area under curve.
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(nonrandomized) population from the same 
group of investigators [6].
With one important exception, the toxicity 
profile identified in these studies was similar 
to that observed in other settings where single 
agent bevacizumab had been evaluated in the 
past. An unexpected relatively high incidence 
of bowel perforations (approximately 10%) 
was noted in one phase 2 trial, with similar 
experiences noted by other investigators [7]. Of 
interest and potentially of considerable clinical 
relevance despite limited data, there appeared 
to be an association identified in this trial 
between the extent of bowel involvement with 
tumor (based on either radiographic evidence 
of “thickened bowel wall” or partial small 
bowel obstruction) and the subsequent risk of 
development of bowel perforation.
A number of investigators have also reported 
nonrandomized phase 2 studies, or retrospective 
reviews of individual institutional experiences, 
combining bevacizumab with cytotoxic agents in 
the treatment of ovarian cancer [8,9]. However, 
based on these uncontrolled reports it remained 
unknown if any hypothesized improvement 
in outcome (eg, response, extended period of 
time to disease progression) was superior to 
alternative strategies, including the sequential 
administration of cytotoxic therapy followed 
by the antiangiogenic agent, or the reverse 
sequence.
PHASE 3 TRIALS OF COMBINATION 
CYTOTOXIC CHEMOTHERAPY 
WITH OR WITHOUT BEVACIZUMAB 
IN THE PRIMARY MANAGEMENT 
OF EPITHELIAL OVARIAN CANCER
At the time of writing this review, the 
preliminary results of three phase 3 randomized 
trials, which examined a potential role for 
bevacizumab when combined with standard 
cytotoxic chemotherapy in the management 
of ovarian cancer, have been reported [10-12]. 
Two of these studies evaluated the addition of 
the antiangiogenic agent with carboplatin plus 
paclitaxel in the primary care setting (Table 2) 
[10,11], while the third trial explored the drug 
in recurrent disease when given with carboplatin 
plus gemcitabine (Table 3) [12].
In the first primary chemotherapy 
treatment trial to be reported, investigators 
from the Gynecologic Oncology Group (GOG) 
randomized patients with stage III and IV ovarian 
cancer to one of three study arms (Table 2)
[10]. Of considerable interest, this study was 
unique in the spectrum of all oncology trials 
exploring a role for antiangiogenic drugs in that 
it specifically addressed two different but highly 
clinically relevant issues associated with the use 
of bevacizumab.
The first question was whether the 
antiangiogenic agent’s activity was based 
exclusively on its ability to potentiate the 
favorable effects of the simultaneously 
administered chemotherapy. This might happen 
because of the drug’s ability to enhance the 
delivery of cytotoxic therapy to the tumor due 
to improved blood supply.
The second question was whether the 
antiangiogenic agent would have a favorable 
impact on outcome, potentially entirely 
independent of the chemotherapy, when 
administered as a “maintenance” approach 
after completing delivery of the cytotoxics. 
A proposed mechanism for such an effect would 
be interference by bevacizumab with the cancer’s 
ability to develop new blood vessels to permit 
local tumor growth or more distant metastatic 
spread.
As outlined in Table 2 [10,11], patients treated 
with bevacizumab both during chemotherapy 
and after completion of cytotoxic therapy 
(“maintenance”) experienced a statistically 
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significant improvement in PFS compared 
with chemotherapy alone (no bevacizumab). 
At the time of the initial study, follow-up was 
not sufficient to make a definitive comment 
regarding overall survival (preliminary data 
shown in Table 2), although there was no 
difference in 1-year survival between this study 
arm and the chemotherapy only “control 
group.”
Of considerable interest, and to the surprise 
of many, there was no difference in PFS between 
patients who received the antiangiogenic 
agent solely during chemotherapy (no 
“maintenance” bevacizumab), compared with 
carboplatin plus paclitaxel alone (Table 2). 
One-year survival was also not different from 
the “control group.”
The second primary ovarian cancer phase 3
bevacizumab trial, which was conducted 
in Europe and Canada, differed in several 
important aspects compared with the GOG 
study (Table 2) [11]. First, this study did not 
employ placebo control. Second, the dose of 
bevacizumab was one-half (7.5 mg/kg every
2 weeks) the dose utilized in the GOG trial
(15 mg/kg). Third, patients with somewhat 
ear l ier  s tage  disease  were  permitted 
entry into the European/Canadian study. 
Finally, this trial had only two arms, a 
“control regimen” of carboplatin plus 
paclitaxel and an experimental program 
that included bevacizumab delivered both 
during chemotherapy and as single agent 
“maintenance” when cytotoxics  were 
discontinued.
Again,  this  s tudy,  which to date 
has only been presented in abstract 
form, revealed a statistically significant 
improvement in PFS in favor of the 
experimental program, with no statistically 
significant impact on overall survival [11].
In an interesting subset analysis, patients 
with the most extensive disease (stage IIIC 
and IV) appeared to experience the greatest 
benefit from the addition of bevacizumab to 
carboplatin and paclitaxel.
Additional follow-up data from both primary 
chemotherapy studies, particularly any influence 
of therapy on overall survival, are awaited with 
considerable interest.
Regimen PFS (median) Preliminary overall survival (median)
GOG trial [10]
Carboplatin/paclitaxel 10.3 months 39.3 months
Carboplatin/paclitaxel + bevacizumab 
(delivered only during chemotherapy)
11.2 months 
(hazard ratio: 0.908; P=0.80)
38.7 months
Carboplatin/paclitaxel + bevacizumab 
(delivered with chemotherapy and as 
single agent “maintenance”)
14.1 months 
(hazard ratio: 0.717; P<0.001
39.7 months
ICON 7 [11]
Carboplatin/paclitaxel 17.4 months Not available
Carboplatin/paclitaxel + bevacizumab 
(delivered with chemotherapy and as 
single agent “maintenance”)
19.8 months 
(hazard ratio: 0.87; P=0.039)
Not available
GOG=Gynecologic Oncology Group, PFS=progression-free survival.
Table 2. Phase 3 trials comparing carboplatin plus paclitaxel with or without bevacizumab as primary chemotherapy of 
epithelial ovarian cancer.
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PHASE 3 TRIAL OF CYTOTOXIC 
CHEMOTHERAPY WITH OR 
WITHOUT BEVACIZUMAB IN 
RECURRENT OVARIAN CANCER
A preliminary report of the results of adding 
bevacizumab to carboplatin plus gemcitabine 
in recurrent ovarian cancer appears to have 
reached similar conclusions to that of the 
previously described primary phase 3 studies 
demonstrating a statistically significant 
improvement in PFS associated with combining 
the antiangiogenic agent with chemotherapy 
(Table 3) [12]. Further, this strategy was 
associated with an increase in the objective 
response rate, compared with carboplatin plus 
gemcitabine alone.
Of note,  while chemotherapy was 
administered for a fixed number of cycles the 
antiangiogenic agent was actually continued 
(assuming acceptable toxicity) until documented 
disease progression rather than being stopped at 
some rather arbitrary time point (eg, six cycles of 
therapy, two cycles beyond “stabilization of the 
disease process”).
While it remains to be determined if the 
demonstrated favorable impact of treatment 
on PFS observed in this trial will be translated 
into a statistically significant difference in 
overall survival, the preliminary study results 
suggest this is a possible outcome. Therefore, it 
is reasonable to inquire why these results may 
differ from what has been observed to date in 
primary disease management studies.
First, as previously noted and in sharp 
contrast to front-line trials where treatment 
was discontinued after 12 (European/
Canadian study) or 15 months (GOG study),
bevacizumab was continued until documented 
disease progression in the recurrent disease study 
[12]. Second, with the more modest impact of 
platinum-based chemotherapy on outcome 
in recurrent disease (compared with primary 
therapy), realistically, a possible favorable 
influence of the antiangiogenic drug on the 
course of illness in this specific setting may have 
been easier to observe.
Again, as with the primary disease 
management studies, the final results of this 
effort are awaited with considerable interest. 
A confirmatory phase 3 trial examining the 
combination of chemotherapy with or without 
bevacizumab in recurrent ovarian cancer is being 
conducted by GOG and remains in progress. 
It is anticipated the preliminary results of 
this trial will be available within the next 
1 to 2 years.
OTHER ANTIANGIOGENIC AGENTS 
BEING STUDIED IN COMBINATION 
WITH CHEMOTHERAPY IN 
EPITHELIAL OVARIAN CANCER
Several phase 2 and phase 3 comparative trials 
have been initiated that explore the clinical 
utility of a number of additional antiangiogenic 
agents (cediranib, pazopanib, BIBF 1120, 
vascular endothelial growth factor-trap, 
Regimen Response rate PFS (median) Overall survival
Carboplatin + gemcitabine 57.4% 8.4 months 29.9 months




12.4 months (hazard ratio: 
0.484; P<0.0001)
35.5 months (hazard ratio: 
0.751; P=0.094)
PFS=progression-free survival.
Table 3. Phase 3 trial comparing carboplatin plus gemcitabine with or without bevacizumab in (potentially) platinum-
sensitive recurrent ovarian cancer [12].
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sorafenib, sunitinib, and AMG 386) when 
combined with cytotoxic chemotherapy in 
managing epithelial ovarian cancer [13].
It is still not known if any agent will be seen 
as superior to bevacizumab in this setting, in 
either terms of improved survival or reduced 
toxicity. It is certainly possible that a future study 
will directly compare the utility of two or more 
antiangiogenic approaches. It is also reasonable 
to consider combining two antiangiogenic 
agents with different mechanisms of biological 
activity as treatment for ovarian cancer. 
However, the potential for enhanced toxicity 
would be realistically a concern in this setting 
[14].
CONCLUSION
Remaining preliminary, existing data support a 
potentially highly relevant role for combining 
cytotoxic chemotherapy with bevacizumab (or 
possibly other antiangiogenic agents) in the 
management of advanced epithelial ovarian 
cancer. However, it is relevant to acknowledge 
that at the present time it remains unknown if 
the planned sequential delivery of chemotherapy 
and antiangiogenic therapy (eg, primary 
chemotherapy with bevacizumab followed by 
single agent maintenance bevacizumab) might 
produce equivalent outcomes and possibly a 
meaningful reduction in the risk of serious 
side effects. Future research in this area appears 
warranted.
While not the focus of this review, one 
final comment is necessary in this discussion 
of a role for antiangiogenic agents in the 
noninvestigative management of ovarian 
cancer. It is recognized that the substantial 
costs associated with many novel antineoplastic 
agents, including antiangiogenic drugs, 
may limit their use despite demonstrated 
improvement in clinically meaningful 
endpoints (eg, time to symptomatic disease 
progression).
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